Abivax SA American Depositary Shares
$ 96.55
-4.28%
12 Jun - close price
- Market Cap 7,694,508,000 USD
- Current Price $ 96.55
- High / Low $ 100.90 / 96.21
- Stock P/E N/A
- Book Value 6.30
- EPS -5.32
- Next Earning Report 2026-09-14
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.45 %
- ROE -1.57 %
- 52 Week High 148.83
- 52 Week Low 5.69
About
Abivax SA is a clinical-stage biotechnology firm focused on pioneering immunotherapies aimed at treating chronic inflammatory diseases and viral infections, with its lead candidate ABX464 currently in clinical trials for ulcerative colitis among other indications. The company distinguishes itself by utilizing a unique approach that integrates antibody-mediated therapies with proprietary compounds, addressing critical unmet medical needs in the healthcare sector. With a robust pipeline and a team of skilled scientists committed to advancing therapeutic innovation, Abivax presents an attractive investment proposition for institutional investors seeking to leverage growth opportunities within the immunotherapy landscape.
Analyst Target Price
$149.09
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-22 | 2026-03-23 | 2025-12-15 | 2025-09-08 | 2025-06-02 | 2025-03-24 | 2024-11-07 | 2024-09-09 | 2024-04-02 | 2024-02-06 | 2023-11-29 | 2023-09-21 |
| Reported EPS | -0.7076 | -1.18 | -2.47 | -0.89 | -0.95 | -0.8143 | -0.72 | -1.01 | -0.7903 | 0 | -0.64 | -0.72 |
| Estimated EPS | -0.8115 | -1.04 | -0.79 | -0.95 | -0.76 | -1.29 | -0.79 | -0.97 | -0.6 | -0.92 | -0.64 | 0 |
| Surprise | 0.1039 | -0.14 | -1.68 | 0.06 | -0.19 | 0.4757 | 0.07 | -0.04 | -0.1903 | 0.92 | 0 | -0.72 |
| Surprise Percentage | 12.8035% | -13.4615% | -212.6582% | 6.3158% | -25% | 36.876% | 8.8608% | -4.1237% | -31.7167% | 100% | 0% | None% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-09-14 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | |
| Currency | EUR |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ABVX
2026-06-10 14:40:14
The Schall Law Firm is investigating Abivax S.A. (NASDAQ: ABVX) on behalf of investors for potential violations of securities laws. This investigation follows a sharp decline in Abivax's share price on June 2, 2026, after its Phase 3 ABTECT trial for obefazimod revealed rare malignancy cases. Investors who suffered losses are encouraged to contact the Schall Law Firm to discuss their rights.
2026-06-10 03:39:14
Abivax announced that its drug abefazimod successfully met the primary endpoint in the Phase III ABTECT clinical trial. This trial evaluated the drug which was administered as a 25mg dose. The positive outcome suggests potential for obefazimod in treating its target condition.
2026-06-09 13:09:26
The Gross Law Firm is alerting investors of ABIVAX Societe Anonyme (NASDAQ: ABVX) about an upcoming securities class action deadline. Shareholders who purchased shares between June 2, 2021, and June 2, 2026, are encouraged to contact the firm regarding potential lead plaintiff appointments. The lawsuit alleges that ABIVAX made false and misleading statements, causing significant losses after rare malignancy cases surfaced in its Phase 3 ulcerative colitis trial.
2026-06-08 12:39:46
The Schall Law Firm has launched an investigation into Abivax S.A. (NASDAQ: ABVX) on behalf of investors, following a sharp decline in share price. The investigation concerns potential violations of securities laws, specifically regarding false or misleading statements and undisclosed information related to rare malignancy cases found in the Phase 3 ABTECT trial for obefazimod. Shareholders who have incurred losses are encouraged to contact the firm to discuss their rights.
2026-06-08 12:39:46
The Schall Law Firm has announced an investigation into Abivax S.A. (NASDAQ: ABVX) on behalf of investors, following a sharp decline in its stock price on June 2, 2026. This investigation stems from the disclosure of rare malignancy cases during Abivax's Phase 3 ABTECT trial for obefazimod. The firm is looking into whether Abivax issued false or misleading statements or failed to disclose critical information to investors.
2026-06-07 22:39:17
Abivax experienced a volatile week as its stock initially plunged due to investor concerns over malignancy signals in its Phase III ABTECT maintenance trial for ulcerative colitis candidate obefazimod. However, the stock rebounded as analysts highlighted the drug's strong efficacy data, which showed high clinical remission rates surpassing other marketed treatments. Despite the safety concerns, many experts believe obefazimod has "best-in-disease" potential and could be a significant new oral agent for inflammatory bowel disease, with an NDA filing planned for late 2026.
